{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:56:20Z","timestamp":1792090580160,"version":"4.4.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006108","name":"U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR002378 (MBV), UL1TR000454 (MBV), and UL1TR000448 (MBV)"],"award-info":[{"award-number":["UL1TR002378 (MBV), UL1TR000454 (MBV), and UL1TR000448 (MBV)"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common liver disease worldwide, yet treatment remains \u201cone size fits all,\u201d despite phenotypic heterogeneity. We analyzed clinical and metabolomics data from 514 children (ages 5-18, 73% male) with biopsy-proven MASLD across three NASH Clinical Research Network studies. Unsupervised clustering of clinical data identified three distinct metabotypes: early-mild (49.4%, youngest, lowest lipids, liver enzymes, insulin resistance), cardiometabolic (36.8%, highest waist circumference, lipids, uric acid, SBP), and inflammatory-fibrotic (13.8%, highest liver enzymes, steatohepatitis, advanced fibrosis). Integrative network and pathway enrichment analyses revealed alterations in tryptophan metabolism within the inflammatory-fibrotic group, including elevated kynurenine pathway metabolites, which were significantly correlated with fibrosis stage. Branched-chain amino acid degradation, butanoate, and purine metabolism demonstrated greater enrichment in the cardiometabolic group. Here, we show that pediatric MASLD subtypes differ in clinical and metabolic features, providing a framework for targeted interventions, with validation needed in independent cohorts.<\/jats:p>","DOI":"10.1038\/s41467-026-69735-z","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T04:45:15Z","timestamp":1771908315000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinically distinct metabotypes of pediatric MASLD identified through unsupervised clustering of NASH CRN data"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3866-2387","authenticated-orcid":false,"given":"Helaina E.","family":"Huneault","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep","family":"Tiwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4670-1497","authenticated-orcid":false,"given":"Zachery R.","family":"Jarrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8889-3477","authenticated-orcid":false,"given":"Matthew Ryan","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Ramirez Tovar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Sanchez-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Gillespie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shasha","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo M.","family":"Carrillo-Larco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay K.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6138-2194","authenticated-orcid":false,"given":"Katherine P.","family":"Yates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8520-7398","authenticated-orcid":false,"given":"Brent A.","family":"Neuschwander-Tetri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey B.","family":"Schwimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavra A.","family":"Xanthakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean P.","family":"Molleston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia A.","family":"Behling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark H.","family":"Fishbein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terryl J.","family":"Hartman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3845-6703","authenticated-orcid":false,"given":"Francisco J.","family":"Pasquel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishikesan","family":"Kamaleswaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2090-0677","authenticated-orcid":false,"given":"Dean P.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean A.","family":"Welsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam B.","family":"Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"69735_CR1","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella, M. E. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 78, 1966\u20131986 (2023).","journal-title":"Hepatology"},{"key":"69735_CR2","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1053\/j.gastro.2020.01.048","volume":"158","author":"D Goldner","year":"2020","unstructured":"Goldner, D. & Lavine, J. E. Nonalcoholic fatty liver disease in children: unique considerations and challenges. Gastroenterology 158, 1967\u20131983.e1961 (2020).","journal-title":"Gastroenterology"},{"key":"69735_CR3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/MPG.0000000000003795","volume":"77","author":"AK Mischel","year":"2023","unstructured":"Mischel, A. K. et al. Prevalence of elevated ALT in adolescents in the US 2011\u20132018. J. Pediatr. Gastroenterol. Nutr. 77, 103\u2013109 (2023).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"69735_CR4","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jpeds.2018.11.021","volume":"207","author":"EL Yu","year":"2019","unstructured":"Yu, E. L. et al. Prevalence of nonalcoholic fatty liver disease in children with obesity. J. Pediatr. 207, 64\u201370 (2019).","journal-title":"J. Pediatr."},{"key":"69735_CR5","doi-asserted-by":"publisher","first-page":"F1000 Faculty R","DOI":"10.12688\/f1000research.24198.1","volume":"9","author":"J Vittorio","year":"2020","unstructured":"Vittorio, J. & Lavine, J. E. Recent advances in understanding and managing pediatric nonalcoholic fatty liver disease. F1000Res 9, F1000 Faculty Rev\u2013F1000 Faculty1377 (2020).","journal-title":"F1000Res"},{"key":"69735_CR6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.psym.2018.09.001","volume":"60","author":"K Karaivazoglou","year":"2019","unstructured":"Karaivazoglou, K., Kalogeropoulou, M., Assimakopoulos, S. & Triantos, C. Psychosocial issues in pediatric nonalcoholic fatty liver disease. Psychosomatics 60, 10\u201317 (2019).","journal-title":"Psychosomatics"},{"key":"69735_CR7","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/j.1365-2036.2009.04181.x","volume":"31","author":"KD Kistler","year":"2010","unstructured":"Kistler, K. D. et al. Symptoms and quality of life in obese children and adolescents with non-alcoholic fatty liver disease. Aliment Pharm. Ther. 31, 396\u2013406 (2010).","journal-title":"Aliment Pharm. Ther."},{"key":"69735_CR8","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/MPG.0b013e31822cdedf","volume":"54","author":"H Gr\u00f8nb\u00e6k","year":"2012","unstructured":"Gr\u00f8nb\u00e6k, H. et al. Effect of a 10-week weight loss camp on fatty liver disease and insulin sensitivity in obese Danish children. J. Pediatr. Gastroenterol. Nutr. 54, 223\u2013228 (2012).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"69735_CR9","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1089\/chi.2013.0022","volume":"9","author":"M Ramon-Krauel","year":"2013","unstructured":"Ramon-Krauel, M. et al. A low-glycemic-load versus low-fat diet in the treatment of fatty liver in obese children. Child Obes. 9, 252\u2013260 (2013).","journal-title":"Child Obes."},{"key":"69735_CR10","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/MPG.0b013e3181d70468","volume":"51","author":"C Pozzato","year":"2010","unstructured":"Pozzato, C. et al. Liver fat change in obese children after a 1-year nutrition-behavior intervention. J. Pediatr. Gastroenterol. Nutr. 51, 331\u2013335 (2010).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"69735_CR11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/ijo.2015.175","volume":"40","author":"BG Koot","year":"2016","unstructured":"Koot, B. G. et al. Intensive lifestyle treatment for non-alcoholic fatty liver disease in children with severe obesity: inpatient versus ambulatory treatment. Int J. Obes. (Lond.) 40, 51\u201357 (2016).","journal-title":"Int J. Obes. (Lond.)"},{"key":"69735_CR12","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1080\/17474124.2019.1595589","volume":"13","author":"L Draijer","year":"2019","unstructured":"Draijer, L., Benninga, M. & Koot, B. Pediatric NAFLD: an overview and recent developments in diagnostics and treatment. Expert Rev. Gastroenterol. Hepatol. 13, 447\u2013461 (2019).","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"69735_CR13","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.4254\/wjh.v13.i11.1584","volume":"13","author":"P Pal","year":"2021","unstructured":"Pal, P., Palui, R. & Ray, S. Heterogeneity of non-alcoholic fatty liver disease: Implications for clinical practice and research activity. World J. Hepatol. 13, 1584\u20131610 (2021).","journal-title":"World J. Hepatol."},{"key":"69735_CR14","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1055\/s-0041-1730927","volume":"41","author":"M Arrese","year":"2021","unstructured":"Arrese, M. et al. Insights into nonalcoholic fatty-liver disease heterogeneity. Semin Liver Dis. 41, 421\u2013434 (2021).","journal-title":"Semin Liver Dis."},{"key":"69735_CR15","first-page":"435","volume":"2","author":"A Lonardo","year":"2021","unstructured":"Lonardo, A. Separating the apples from the oranges: from NAFLD heterogeneity to personalized medicine. Exploration Med. 2, 435\u2013442 (2021).","journal-title":"Exploration Med."},{"key":"69735_CR16","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1038\/s41588-023-01497-6","volume":"55","author":"Y Chen","year":"2023","unstructured":"Chen, Y. et al. Genome-wide association meta-analysis identifies 17 loci associated with nonalcoholic fatty liver disease. Nat. Genet 55, 1640\u20131650 (2023).","journal-title":"Nat. Genet"},{"key":"69735_CR17","doi-asserted-by":"publisher","first-page":"830","DOI":"10.3390\/jpm13050830","volume":"13","author":"L Valenzuela-Vallejo","year":"2023","unstructured":"Valenzuela-Vallejo, L., Sanoudou, D. & Mantzoros, C. S. Precision medicine in fatty liver disease\/non-alcoholic fatty liver disease. J. Personalized Med. 13, 830 (2023).","journal-title":"J. Personalized Med."},{"key":"69735_CR18","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s11154-023-09820-6","volume":"24","author":"SM Francque","year":"2023","unstructured":"Francque, S. M. Towards precision medicine in non-alcoholic fatty liver disease. Rev. Endocr. Metab. Disord. 24, 885\u2013899 (2023).","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"69735_CR19","first-page":"109","volume":"13","author":"N Stefan","year":"2025","unstructured":"Stefan, N., Yki-J\u00e4rvinen, H. & Neuschwander-Tetri, B. A. Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment.  Lancet Diab Endocrinol. 13, 109\u2013121 (2025).","journal-title":"Lancet Diab Endocrinol."},{"key":"69735_CR20","first-page":"91","volume":"25","author":"M Vandromme","year":"2020","unstructured":"Vandromme, M. et al. Automated phenotyping of patients with non-alcoholic fatty liver disease reveals clinically relevant disease subtypes. Pac. Symp. Biocomput 25, 91\u2013102 (2020).","journal-title":"Pac. Symp. Biocomput"},{"key":"69735_CR21","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3350\/cmh.2021.0127","volume":"27","author":"HY Kim","year":"2021","unstructured":"Kim, H. Y. Recent advances in nonalcoholic fatty liver disease metabolomics. Clin. Mol. Hepatol. 27, 553\u2013559 (2021).","journal-title":"Clin. Mol. Hepatol."},{"key":"69735_CR22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41419-017-0124-2","volume":"9","author":"A Sartini","year":"2018","unstructured":"Sartini, A. et al. Non-alcoholic fatty liver disease phenotypes in patients with inflammatory bowel disease. Cell Death Dis. 9, 87 (2018).","journal-title":"Cell Death Dis."},{"key":"69735_CR23","doi-asserted-by":"publisher","first-page":"S564","DOI":"10.14309\/01.ajg.0000778428.37400.23","volume":"116","author":"S Chung","year":"2021","unstructured":"Chung, S. et al. Computable phenotypes for NAFLD and NASH Identify patients with significant comorbidities yet most remain undiagnosed.  Am. J. Gastroenterol. 116, S564 (2021).","journal-title":"Am. J. Gastroenterol."},{"key":"69735_CR24","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/cld.1199","volume":"19","author":"S Saffo","year":"2022","unstructured":"Saffo, S. & Do, A. Clinical Phenotyping and the application of precision medicine in MAFLD. Clin. Liver Dis. 19, 227\u2013233 (2022).","journal-title":"Clin. Liver Dis."},{"key":"69735_CR25","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.jhep.2020.10.015","volume":"74","author":"SP Singh","year":"2021","unstructured":"Singh, S. P. et al. Non-alcoholic fatty liver disease: not time for an obituary just yet!. J. Hepatol. 74, 972\u2013974 (2021).","journal-title":"J. Hepatol."},{"key":"69735_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2015.68","volume":"2","author":"W Wruck","year":"2015","unstructured":"Wruck, W. et al. Multi-omic profiles of human non-alcoholic fatty liver disease tissue highlight heterogenic phenotypes. Sci. Data 2, 150068 (2015).","journal-title":"Sci. Data"},{"key":"69735_CR27","doi-asserted-by":"publisher","first-page":"3624","DOI":"10.1038\/s41591-024-03283-1","volume":"30","author":"V Raverdy","year":"2024","unstructured":"Raverdy, V. et al. Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease. Nat. Med. 30, 3624\u20133633 (2024).","journal-title":"Nat. Med."},{"key":"69735_CR28","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1007\/s12325-021-01690-1","volume":"38","author":"A Lonardo","year":"2021","unstructured":"Lonardo, A., Arab, J. P. & Arrese, M. Perspectives on precision medicine approaches to NAFLD diagnosis and management. Adv. Ther. 38, 2130\u20132158 (2021).","journal-title":"Adv. Ther."},{"key":"69735_CR29","doi-asserted-by":"publisher","first-page":"9523","DOI":"10.3390\/ijerph17249523","volume":"17","author":"A Sarr\u00eda-Santamera","year":"2020","unstructured":"Sarr\u00eda-Santamera, A., Orazumbekova, B., Maulenkul, T., Gaipov, A. & Atageldiyeva, K. The identification of diabetes mellitus subtypes applying cluster analysis techniques: a systematic review. Int. J. Environ. Res. Public Health 17, 9523 (2020).","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"69735_CR30","doi-asserted-by":"publisher","first-page":"272","DOI":"10.3390\/jpm11040272","volume":"11","author":"S Ferro","year":"2021","unstructured":"Ferro, S. et al. Phenomapping of patients with primary breast cancer using machine learning-based unsupervised cluster analysis. J. personalized Med. 11, 272 (2021).","journal-title":"J. personalized Med."},{"key":"69735_CR31","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S2213-8587(18)30051-2","volume":"6","author":"E Ahlqvist","year":"2018","unstructured":"Ahlqvist, E. et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables.  Lancet Diab Endocrinol. 6, 361\u2013369 (2018).","journal-title":"Lancet Diab Endocrinol."},{"key":"69735_CR32","doi-asserted-by":"publisher","first-page":"8836","DOI":"10.1021\/acs.analchem.0c00338","volume":"92","author":"KH Liu","year":"2020","unstructured":"Liu, K. H. et al. Reference standardization for quantification and harmonization of large-scale metabolomics. Anal. Chem. 92, 8836\u20138844 (2020).","journal-title":"Anal. Chem."},{"key":"69735_CR33","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1515\/BC.2002.042","volume":"383","author":"GI Giles","year":"2002","unstructured":"Giles, G. I. & Jacob, C. Reactive sulfur species: an emerging concept in oxidative stress. Biol. Chem. 383, 375\u2013388 (2002).","journal-title":"Biol. Chem."},{"key":"69735_CR34","doi-asserted-by":"publisher","first-page":"e0295441","DOI":"10.1371\/journal.pone.0295441","volume":"18","author":"RM Swain","year":"2023","unstructured":"Swain, R. M., Sanchez, A., Gutierrez, D. A., Varela-Ramirez, A. & Aguilera, R. J. Thiophene derivative inflicts cytotoxicity via an intrinsic apoptotic pathway on human acute lymphoblastic leukemia cells. PLoS One 18, e0295441 (2023).","journal-title":"PLoS One"},{"key":"69735_CR35","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/hep.20842","volume":"42","author":"JB Schwimmer","year":"2005","unstructured":"Schwimmer, J. B. et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 42, 641\u2013649 (2005).","journal-title":"Hepatology"},{"key":"69735_CR36","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.cgh.2017.02.030","volume":"16","author":"JA Africa","year":"2018","unstructured":"Africa, J. A. et al. In children with nonalcoholic fatty liver disease, zone 1 steatosis is associated with advanced fibrosis. Clin. Gastroenterol. Hepatol. 16, 438\u2013446.e431 (2018).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"69735_CR37","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/joim.13375","volume":"291","author":"J Bor\u00e9n","year":"2022","unstructured":"Bor\u00e9n, J. et al. Effects of PNPLA3 I148M on hepatic lipid and very-low-density lipoprotein metabolism in humans. J. Intern. Med. 291, 218\u2013223 (2022).","journal-title":"J. Intern. Med."},{"key":"69735_CR38","doi-asserted-by":"publisher","first-page":"e067203","DOI":"10.1136\/bmjopen-2022-067203","volume":"12","author":"RM Carrillo-Larco","year":"2022","unstructured":"Carrillo-Larco, R. M. et al. Phenotypes of non-alcoholic fatty liver disease (NAFLD) and all-cause mortality: unsupervised machine learning analysis of NHANES III. BMJ Open 12, e067203 (2022).","journal-title":"BMJ Open"},{"key":"69735_CR39","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000016","volume":"7","author":"J Yi","year":"2023","unstructured":"Yi, J., Wang, L., Guo, J. & Ren, X. Novel metabolic phenotypes for extrahepatic complication of nonalcoholic fatty liver disease. Hepatol. Commun. 7, e0016 (2023).","journal-title":"Hepatol. Commun."},{"key":"69735_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2022.155294","volume":"136","author":"J Ye","year":"2022","unstructured":"Ye, J. et al. Novel metabolic classification for extrahepatic complication of metabolic associated fatty liver disease: a data-driven cluster analysis with international validation. Metabolism 136, 155294 (2022).","journal-title":"Metabolism"},{"key":"69735_CR41","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-016-0751-5","volume":"16","author":"MM Kelsey","year":"2016","unstructured":"Kelsey, M. M. & Zeitler, P. S. Insulin resistance of puberty. Curr. Diab Rep. 16, 64 (2016).","journal-title":"Curr. Diab Rep."},{"key":"69735_CR42","doi-asserted-by":"publisher","first-page":"3614","DOI":"10.1038\/s41591-024-03284-0","volume":"30","author":"O Jamialahmadi","year":"2024","unstructured":"Jamialahmadi, O. et al. Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease. Nat. Med. 30, 3614\u20133623 (2024).","journal-title":"Nat. Med."},{"key":"69735_CR43","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1159\/000520734","volume":"86","author":"JD Roe","year":"2021","unstructured":"Roe, J. D., Garcia, L. A., Klimentidis, Y. C. & Coletta, D. K. Association of PNPLA3 I148M with liver disease biomarkers in Latinos. Hum. Heredity 86, 21\u201327 (2021).","journal-title":"Hum. Heredity"},{"key":"69735_CR44","doi-asserted-by":"publisher","first-page":"130","DOI":"10.4239\/wjd.v14.i3.130","volume":"14","author":"PV Dludla","year":"2023","unstructured":"Dludla, P. V. et al. Pancreatic \u03b2-cell dysfunction in type 2 diabetes: implications of inflammation and oxidative stress. World J. Diab 14, 130\u2013146 (2023).","journal-title":"World J. Diab"},{"key":"69735_CR45","doi-asserted-by":"publisher","first-page":"174","DOI":"10.21037\/atm-20-3594","volume":"9","author":"Q Zhou","year":"2021","unstructured":"Zhou, Q., Shi, Y., Chen, C., Wu, F. & Chen, Z. A narrative review of the roles of indoleamine 2, 3-dioxygenase and tryptophan-2, 3-dioxygenase in liver diseases. Ann. Transl. Med. 9, 174 (2021).","journal-title":"Ann. Transl. Med."},{"key":"69735_CR46","doi-asserted-by":"crossref","unstructured":"Teunis, C., Nieuwdorp, M. & Hanssen, N. Interactions between tryptophan metabolism, the gut microbiome and the immune system as potential drivers of non-alcoholic fatty liver disease (NAFLD) and metabolic diseases. Metabolites 12, 514 (2022).","DOI":"10.3390\/metabo12060514"},{"key":"69735_CR47","doi-asserted-by":"publisher","DOI":"10.1111\/eci.14279","volume":"54","author":"C Arto","year":"2024","unstructured":"Arto, C. et al. Metabolic profiling of tryptophan pathways: Implications for obesity and metabolic dysfunction-associated steatotic liver disease. Eur. J. Clin. Investig. 54, e14279 (2024).","journal-title":"Eur. J. Clin. Investig."},{"key":"69735_CR48","doi-asserted-by":"publisher","first-page":"34800","DOI":"10.1074\/jbc.M111.235473","volume":"286","author":"Y Osawa","year":"2011","unstructured":"Osawa, Y. et al. L-tryptophan-mediated enhancement of susceptibility to nonalcoholic fatty liver disease is dependent on the mammalian target of rapamycin. J. Biol. Chem. 286, 34800\u201334808 (2011).","journal-title":"J. Biol. Chem."},{"key":"69735_CR49","first-page":"56","volume":"47","author":"GF Oxenkrug","year":"2010","unstructured":"Oxenkrug, G. F. Tryptophan kynurenine metabolism as a common mediator of genetic and environmental impacts in major depressive disorder: the serotonin hypothesis revisited 40 years later. Isr. J. Psychiatry Relat. Sci. 47, 56\u201363 (2010).","journal-title":"Isr. J. Psychiatry Relat. Sci."},{"key":"69735_CR50","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.2174\/0929867321666140304105526","volume":"21","author":"H Mangge","year":"2014","unstructured":"Mangge, H. et al. Disturbed tryptophan metabolism in cardiovascular disease. Curr. Med Chem. 21, 1931\u20131937 (2014).","journal-title":"Curr. Med Chem."},{"key":"69735_CR51","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s10620-015-3871-x","volume":"61","author":"MV Machado","year":"2016","unstructured":"Machado, M. V. et al. Vitamin B5 and N-acetylcysteine in nonalcoholic steatohepatitis: a preclinical study in a dietary mouse model. Dig. Dis. Sci. 61, 137\u2013148 (2016).","journal-title":"Dig. Dis. Sci."},{"key":"69735_CR52","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.csbj.2024.01.007","volume":"23","author":"J Chen","year":"2024","unstructured":"Chen, J. et al. Distinct changes in serum metabolites and lipid species in the onset and progression of NAFLD in obese chinese. Comput. Struct. Biotechnol. J. 23, 791\u2013800 (2024).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"69735_CR53","first-page":"21","volume":"1","author":"SA Gabr","year":"2016","unstructured":"Gabr, S. A., Alghadir, A. H., Sherif, Y. E. & Ghfar, A. A. Hydroxyproline as a Biomarker in Liver. Biomark. Liver Dis. 1, 21 (2016).","journal-title":"Biomark. Liver Dis."},{"key":"69735_CR54","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.3390\/medicina59101785","volume":"59","author":"N Garibay-Nieto","year":"2023","unstructured":"Garibay-Nieto, N. et al. Metabolomic phenotype of hepatic steatosis and fibrosis in mexican children living with obesity. Medicina 59, 1785 (2023).","journal-title":"Medicina"},{"key":"69735_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-55845-5","volume":"14","author":"X Yang","year":"2024","unstructured":"Yang, X. et al. Serum uric acid levels and prognosis of patients with non-alcoholic fatty liver disease. Sci. Rep. 14, 5923 (2024).","journal-title":"Sci. Rep."},{"key":"69735_CR56","doi-asserted-by":"publisher","first-page":"4583","DOI":"10.1080\/10408398.2024.2392150","volume":"65","author":"MF Faienza","year":"2025","unstructured":"Faienza, M. F. et al. Dietary fructose: from uric acid to a metabolic switch in pediatric metabolic dysfunction-associated steatotic liver disease. Crit. Rev. Food Sci. Nutr. 65, 4583\u20134598 (2025).","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"69735_CR57","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3390\/nu11030705","volume":"11","author":"EH van den Berg","year":"2019","unstructured":"van den Berg, E. H. et al. Non-alcoholic fatty liver disease and risk of incident type 2 diabetes: role of circulating branched-chain amino acids. Nutrients 11, 705 (2019).","journal-title":"Nutrients"},{"key":"69735_CR58","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41387-022-00213-3","volume":"12","author":"F Vanweert","year":"2022","unstructured":"Vanweert, F., Schrauwen, P. & Phielix, E. Role of branched-chain amino acid metabolism in the pathogenesis of obesity and type 2 diabetes-related metabolic disturbances BCAA metabolism in type 2 diabetes. Nutr. Diab 12, 35 (2022).","journal-title":"Nutr. Diab"},{"key":"69735_CR59","doi-asserted-by":"crossref","unstructured":"Lo, E. K. K. et al. The emerging role of branched-chain amino acids in liver diseases. Biomedicines 10, 6 (2022).","DOI":"10.3390\/biomedicines10061444"},{"key":"69735_CR60","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1136\/gutjnl-2019-318811","volume":"69","author":"S Sookoian","year":"2020","unstructured":"Sookoian, S. et al. Intrahepatic bacterial metataxonomic signature in non-alcoholic fatty liver disease. Gut 69, 1483\u20131491 (2020).","journal-title":"Gut"},{"key":"69735_CR61","doi-asserted-by":"publisher","first-page":"100073","DOI":"10.1016\/j.jlr.2021.100073","volume":"62","author":"CJ Pirola","year":"2021","unstructured":"Pirola, C. J. & Sookoian, S. The lipidome in nonalcoholic fatty liver disease: actionable targets. J. Lipid Res 62, 100073 (2021).","journal-title":"J. Lipid Res"},{"key":"69735_CR62","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/biom12010056","volume":"12","author":"N Vallianou","year":"2022","unstructured":"Vallianou, N. et al. Understanding the role of the gut microbiome and microbial metabolites in non-alcoholic fatty liver disease: current evidence and perspectives. Biomolecules 12, 56 (2022).","journal-title":"Biomolecules"},{"key":"69735_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-020-02658-5","volume":"18","author":"M Subramanian","year":"2020","unstructured":"Subramanian, M. et al. Precision medicine in the era of artificial intelligence: implications in chronic disease management. J. Transl. Med. 18, 1\u201312 (2020).","journal-title":"J. Transl. Med."},{"key":"69735_CR64","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1053\/j.gastro.2008.08.050","volume":"135","author":"HM Patton","year":"2008","unstructured":"Patton, H. M. et al. Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis. Gastroenterology 135, 1961\u20131971.e1962 (2008).","journal-title":"Gastroenterology"},{"key":"69735_CR65","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1001\/jama.2011.520","volume":"305","author":"JE Lavine","year":"2011","unstructured":"Lavine, J. E. et al. Effect of Vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the tonic randomized controlled trial. JAMA 305, 1659\u20131668 (2011).","journal-title":"JAMA"},{"key":"69735_CR66","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.cct.2009.09.001","volume":"31","author":"JE Lavine","year":"2010","unstructured":"Lavine, J. E. et al. Treatment of nonalcoholic fatty liver disease in children: TONIC trial design. Contemp. Clin. Trials 31, 62\u201370 (2010).","journal-title":"Contemp. Clin. Trials"},{"key":"69735_CR67","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/ejcn.2012.203","volume":"67","author":"DM Harrington","year":"2013","unstructured":"Harrington, D. M., Staiano, A. E., Broyles, S. T., Gupta, A. K. & Katzmarzyk, P. T. BMI percentiles for the identification of abdominal obesity and metabolic risk in children and adolescents: evidence in support of the CDC 95th percentile. Eur. J. Clin. Nutr. 67, 218\u2013222 (2013).","journal-title":"Eur. J. Clin. Nutr."},{"key":"69735_CR68","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","volume":"18","author":"WT Friedewald","year":"1972","unstructured":"Friedewald, W. T., Levy, R. I. & Fredrickson, D. S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18, 499\u2013502 (1972).","journal-title":"Clin. Chem."},{"key":"69735_CR69","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.2337\/diacare.27.6.1487","volume":"27","author":"TM Wallace","year":"2004","unstructured":"Wallace, T. M., Levy, J. C. & Matthews, D. R. Use and abuse of HOMA modeling. Diab Care 27, 1487\u20131495 (2004).","journal-title":"Diab Care"},{"key":"69735_CR70","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1001\/jama.2020.20122","volume":"324","author":"UPST Force","year":"2020","unstructured":"Force, U. P. S. T. Screening for high blood pressure in children and adolescents: US preventive services task force recommendation statement. JAMA 324, 1878\u20131883 (2020).","journal-title":"JAMA"},{"key":"69735_CR71","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner, D. E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313\u20131321 (2005).","journal-title":"Hepatology"},{"key":"69735_CR72","first-page":"259A","volume":"44","author":"DE Kleiner","year":"2006","unstructured":"Kleiner, D. E. et al. Comparison of adult and pediatric NAFLD\u2014confirmation of a second pattern of progressive fatty liver disease in children: 189. Hepatology 44, 259A\u2013260A (2006).","journal-title":"Hepatology"},{"key":"69735_CR73","doi-asserted-by":"publisher","first-page":"e1912565","DOI":"10.1001\/jamanetworkopen.2019.12565","volume":"2","author":"DE Kleiner","year":"2019","unstructured":"Kleiner, D. E. et al. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease. JAMA Netw. Open 2, e1912565 (2019).","journal-title":"JAMA Netw. Open"},{"key":"69735_CR74","doi-asserted-by":"crossref","unstructured":"Kronthaler, F. & Z\u00f6llner, S. Data analysis with RStudio. Data Analysis with RStudio, (2021).","DOI":"10.1007\/978-3-662-62518-7"},{"key":"69735_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v061.i06","volume":"61","author":"M Charrad","year":"2014","unstructured":"Charrad, M., Ghazzali, N., Boiteau, V. & Niknafs, A. NbClust: an R package for determining the relevant number of clusters in a data set. J. Stat. Softw. 61, 1\u201336 (2014).","journal-title":"J. Stat. Softw."},{"key":"69735_CR76","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria https:\/\/R-project.org\/ (2020)."},{"key":"69735_CR77","doi-asserted-by":"crossref","unstructured":"Kassambara, A. & Mundt, F. factoextra: Extract and visualize the results of multivariate data analyses. R package version 1.0.7 https:\/\/CRAN.R-project.org\/package=factoextra (2017).","DOI":"10.32614\/CRAN.package.factoextra"},{"key":"69735_CR78","first-page":"100","volume":"28","author":"JA Hartigan","year":"1979","unstructured":"Hartigan, J. A. & Wong, M. A. Algorithm AS 136: A k-means clustering algorithm. J. R. Stat. Soc. Ser. c. (Appl. Stat.) 28, 100\u2013108 (1979).","journal-title":"J. R. Stat. Soc. Ser. c. (Appl. Stat.)"},{"key":"69735_CR79","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.taap.2018.12.001","volume":"363","author":"DI Walker","year":"2019","unstructured":"Walker, D. I. et al. Metabolome-wide association study of anti-epileptic drug treatment during pregnancy. Toxicol. Appl Pharm. 363, 122\u2013130 (2019).","journal-title":"Toxicol. Appl Pharm."},{"key":"69735_CR80","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1097\/JOM.0000000000000773","volume":"58","author":"KH Liu","year":"2016","unstructured":"Liu, K. H. et al. High-resolution metabolomics assessment of military personnel: evaluating analytical strategies for chemical detection. J. Occup. Environ. Med. 58, S53\u2013S61 (2016).","journal-title":"J. Occup. Environ. Med."},{"key":"69735_CR81","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1093\/bioinformatics\/btp291","volume":"25","author":"T Yu","year":"2009","unstructured":"Yu, T., Park, Y., Johnson, J. M. & Jones, D. P. apLCMS-adaptive processing of high-resolution LC\/MS data. Bioinformatics 25, 1930\u20131936 (2009).","journal-title":"Bioinformatics"},{"key":"69735_CR82","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-15","volume":"14","author":"K Uppal","year":"2013","unstructured":"Uppal, K. et al. xMSanalyzer: automated pipeline for improved feature detection and downstream analysis of large-scale, non-targeted metabolomics data. BMC Bioinforma. 14, 15 (2013).","journal-title":"BMC Bioinforma."},{"key":"69735_CR83","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/biostatistics\/kxj037","volume":"8","author":"WE Johnson","year":"2007","unstructured":"Johnson, W. E., Li, C. & Rabinovic, A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8, 118\u2013127 (2007).","journal-title":"Biostatistics"},{"key":"69735_CR84","doi-asserted-by":"crossref","unstructured":"Tugizimana, F., Steenkamp, P. A., Piater, L. A. & Dubery, I. A. A conversation on data mining strategies in LC-MS untargeted metabolomics: pre-processing and pre-treatment steps. Metabolites 6, 40 (2016).","DOI":"10.3390\/metabo6040040"},{"key":"69735_CR85","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1093\/toxsci\/kfv198","volume":"148","author":"Y-M Go","year":"2015","unstructured":"Go, Y.-M. et al. Reference Standardization for Mass Spectrometry and High-resolution Metabolomics Applications to Exposome Research. Toxicol. Sci. 148, 531\u2013543 (2015).","journal-title":"Toxicol. Sci."},{"key":"69735_CR86","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1021\/acs.analchem.6b01214","volume":"89","author":"K Uppal","year":"2017","unstructured":"Uppal, K., Walker, D. I. & Jones, D. P. xMSannotator: An R Package for Network-Based Annotation of High-Resolution Metabolomics Data. Anal. Chem. 89, 1063\u20131067 (2017).","journal-title":"Anal. Chem."},{"key":"69735_CR87","doi-asserted-by":"publisher","first-page":"e1003123","DOI":"10.1371\/journal.pcbi.1003123","volume":"9","author":"S Li","year":"2013","unstructured":"Li, S. et al. Predicting network activity from high throughput metabolomics. PLoS Comput Biol. 9, e1003123 (2013).","journal-title":"PLoS Comput Biol."},{"key":"69735_CR88","doi-asserted-by":"publisher","first-page":"W398","DOI":"10.1093\/nar\/gkae253","volume":"52","author":"Z Pang","year":"2024","unstructured":"Pang, Z. et al. MetaboAnalyst 6.0: towards a unified platform for metabolomics data processing, analysis and interpretation. Nucleic Acids Res 52, W398\u2013w406 (2024).","journal-title":"Nucleic Acids Res"},{"key":"69735_CR89","first-page":"790","volume":"1","author":"R Kolde","year":"2015","unstructured":"Kolde, R. & Kolde, M. R. Package \u2018pheatmap\u2019. R. package 1, 790 (2015).","journal-title":"R. package"},{"key":"69735_CR90","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/wics.147","volume":"3","author":"H Wickham","year":"2011","unstructured":"Wickham, H. ggplot2. Wiley Interdiscip. Rev.: Comput. Stat. 3, 180\u2013185 (2011).","journal-title":"Wiley Interdiscip. Rev.: Comput. Stat."},{"key":"69735_CR91","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1093\/bioinformatics\/btx656","volume":"34","author":"K Uppal","year":"2018","unstructured":"Uppal, K., Ma, C., Go, Y. M., Jones, D. P. & Wren, J. xMWAS: a data-driven integration and differential network analysis tool. Bioinformatics 34, 701\u2013702 (2018).","journal-title":"Bioinformatics"},{"key":"69735_CR92","doi-asserted-by":"publisher","DOI":"10.1186\/1756-0381-5-19","volume":"5","author":"I Gonz\u00e1lez","year":"2012","unstructured":"Gonz\u00e1lez, I., Cao, K. A., Davis, M. J. & D\u00e9jean, S. Visualising associations between paired \u2018omics\u2019 data sets. BioData Min. 5, 19 (2012).","journal-title":"BioData Min."},{"key":"69735_CR93","doi-asserted-by":"crossref","unstructured":"Blondel, V., Guillaume, J.-L., Lambiotte, R. & Lefebvre, E. Fast Unfolding of Communities in Large Networks. J. Stat. Mech. Theory Exp. 2008, P10008 (2008).","DOI":"10.1088\/1742-5468\/2008\/10\/P10008"},{"key":"69735_CR94","first-page":"837","volume":"18","author":"Y Lichtblau","year":"2016","unstructured":"Lichtblau, Y. et al. Comparative assessment of differential network analysis methods. Brief. Bioinforma. 18, 837\u2013850 (2016).","journal-title":"Brief. Bioinforma."},{"key":"69735_CR95","doi-asserted-by":"publisher","first-page":"1240002","DOI":"10.1142\/S0219720012400021","volume":"10","author":"O Odibat","year":"2012","unstructured":"Odibat, O. & Reddy, C. K. Ranking differential hubs in gene co-expression networks. J. Bioinforma. Comput. Biol. 10, 1240002 (2012).","journal-title":"J. Bioinforma. Comput. Biol."},{"key":"69735_CR96","first-page":"235","volume":"2019","author":"FE Harrell Jr","year":"2019","unstructured":"Harrell, F. E. Jr & Harrell, M. F. E. Jr Package \u2018hmisc\u2019. CRAN2018 2019, 235\u2013236 (2019).","journal-title":"CRAN2018"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69735-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69735-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69735-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T19:14:59Z","timestamp":1774984499000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69735-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":96,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["69735"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-69735-z","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"assertion":[{"value":"12 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MBV serves as a consultant to Boehringer Ingelheim, Novo Nordisk, Eli Lilly, Intercept, Takeda, and Alberio. She has stock or stock options in Thiogenesis and Tern Pharmaceuticals. Her institution has received research grants (or in-kind research services) from Target Real World Evidence, Quest, Labcorp, and Sonic Incytes Medical Corp. JPM has research grant funding from Gilead, Abbvie, Albireo, and Mirum. BANT: Advisor or consultant: Abbvie, Akero, Aldeyra, Aligos, Arrowhead, Corcept, Galectin, GSK, Hepion, HistoIndex, Madrigal, Merck, Mirum, Pfizer, Sagimet, Senseion; Stock options: HepGene, HeptaBio; Institutional research grants: Madrigal. SAX: Institutional research grants: Target Real World Evidence. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3107"}}